Written question asked by Henry Smith (Conservative) on Wednesday, 11 May 2022, in the House of Commons. It was due for an answer on Monday, 16 May 2022. It was answered by Maggie Throup (Conservative) on Tuesday, 17 May 2022 on behalf of the Department of Health and Social Care.
Tixagevimab/cilgavimab
- Question
-
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 28 April 2022 to Question 141960, what progress has been made on assessing Evusheld for treating immunocompromised patients.
- Answer
-
The UK Health Security Agency has yet to complete testing on Evusheld’s efficacy against the Omicron variant. The timing of these results is dependent on the testing assays being completed successfully, which will inform any decisions on potential deployment.
Secondary information
- Type
- Written question
- Reference
- 689
- Session
- 2022-23
- Related items
- Grouped for answer
- Yes
- Subjects
- Immunosuppression Tixagevimab/cilgavimab
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2024-05-24 10:05:42 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/689
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/689
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/689